Administration in the mid-to-high dose cohorts of the gene therapy trial will pause pending further evaluation.

Two dose-limiting toxicities have been recorded in uniQure’s trial evaluating an investigational AAV gene therapy designed to ...

Pfizer made one thing clear this week: It's officially back in the obesity race.

Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its ...

K36 Therapeutics, Inc. ("K36"), a privately held clinical-stage biotechnology company developing novel targeted therapies for ...

Oncology specialists should inform patients about a risk of serious toxicity related to dihydropyrimidine dehydrogenase (DPD) ...

FDA priority review seeks marstacimab label expansion to ≥6 years with inhibitors and ages 6–11 without inhibitors, addressing populations with limited efficacy from factor replacement and high unmet ...

“This is an early but exciting step toward recharging aging tissues using their own biological machinery,” Gaharwar says in ...

Corbus Pharmaceuticals maintains a 'Hold' rating as it advances CRB-701 for HNSCC and CRB-913 for obesity. Click here to read ...

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...

Explore how a light-triggered microneedle patch delivered IVF hormones in animals and what it could mean for future timed ...